Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
First Claim
1. The method for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase in an animal, comprising administering an effective amount of a compound of the formula:
- ##STR23## wherein;
X is O, S, S(O), S(O)2, CR9, or NR10 ;
W is independently;
(1) --AN(OM)C(O)N(R3)R4, --AN(R3)C(O)N(OM)R4, --AN(OM)C(O)R4, --AC(O)N(OM)R4, --N(OM)C(O)N(R3)R4, --N(R3) C(O)N(OM)R4, --N(OM)C(O)R4, --C(O)N(OM)R4, --OR6 N(R5)R6 --(C5 H4 N)R6 R7, --OR6 N(COR5)R6 --(C5 H4 N)R6 R7, --OR6 OC(O)N(COR5)R6 --(C5 H4 N)R6 R7, --OR6 O(CO)N(CO2 R6)R6 (C5 H4 N)R6 R7, --A(C5 H4 N)R6 R7, or --OR6 N(CO2 R5)R6 --(C5 H4 N)R6 R7;
(2) an amidohydroxyurea of the formula;
--N(R19)C(O)C(R19)N(OM)C(O)NHR20, --C(O)N(R19)C(R19)N(OM)C(O)NHR20, --AN(R19)C(O)C(R19)N(OM)C(O)NHR20, --AC(O)N(R19)C(R19)N(OM)C(O)NHR20, --NHC(O)N(OM)C(R19)C(O)N(R19)2 ;
or --NHC(O)N(OM)C(R19)N(R19)C(O)R19 ;
(3) an oxalkane of the structure;
##STR24## wherein n and m are independently 1-4;
(4) a thioalkane of the structure;
##STR25## or (5) a quinolylmethoxy of the structure;
##STR26## n is 1 or 2;
m is 1, 2 or 3;
p is 0 or 1;
A is alkyl, alkenyl, alkynyl, alkyaryl, aralkyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, --C1-10 alkyl(oxy)C1-10 alkyl, --C1-10 alkyl(thio)C1-10 alkyl, --N(R3)C(O)alkyl, --N(R3)C(O)alkenyl, --N(R3)C(O)alkynyl, --N(R3)C(O)(alkyl)oxy(alkyl), --N(R3)C(O) (alkyl)thio(alkyl), --N(R3)C(O)N(alkyl), --N(R3)C(O)N(alkenyl), --N(R3)C(O)N(alkynyl), --N(R3)C(O)N(alkyl)oxy(alkyl), --N(R3)C(O)N(alkyl)thio(alkyl), --N(R3)C(O2)alkyl, --N(R3)C(O2)alkenyl, --N(R3)C(O2)alkynyl, --N(R3)C(O2)(alkyl)oxy(alkyl), --N(R3)C(O2)(alkyl)thio(alkyl) --OC(O2)alkyl, --OC(O2)alkenyl, --OC(O2)alkynyl, --OC(O2)(alkyl)oxy(alkyl), --OC(O2)(alkyl)thio(alkyl), --N(R3)C(S)alkyl, --N(R3)C(S)alkenyl, --N(R3)C(S)alkynyl, --N(R3)C(S)(alkyl)oxy(alkyl), --N(R3)C(S)(alkyl)thio(alkyl), --N(R3)C(S)N(alkyl), --N(R3)C(S)N(alkenyl), --N(R3)C(S)N(alkynyl), --N(R3)C(S)N(alkyl)oxy(alkyl), --N(R3)C(S)N(alkyl)thio(alkyl), --N(R3)C(S)S(alkyl), --N(R3)C(S)S(alkenyl), --N(R3)C(S)S(alkynyl), --N(R3)C(S)S(alkyl)oxy(alkyl), --N(R3)C(S)S(alkyl)thio(alkyl), --SC(S)S(alkyl), --SC(S)S(alkenyl), --SC(S)S(alkynyl), --SC(S)S(alkyl)oxy(alkyl), and --SC(S)S(alkyl)thio(alkyl);
M is hydrogen, a pharmaceutically acceptable cation, or a metabolically cleavable leaving group;
Y is independently;
(a) hydrogen;
(b) R1-6, R8, R10, --OR3, --OR11, --OR12, R3 S--, R5 S, R3 SO--, R5 SO--, R3 SO2 --, R5 SO2 --, CF3 O--, CF3 S--, CF3 SO--, --CF3 SO2, --OCH2 oxycyclopropyl, --OCH2 C(O)OR3, --OCH2 OR3, --OCH2 C(O)R3, --OCH2 C3-8 cycloalkyl, --OCH2 CH(R)R3, --OCH2 cyclopropyl, --OCH2 --aryl, --OCH2 CH(OH)CH2 OH, aryl--CH2 --SO2 --, (R3)2 CHCH2 SO2 --, --CH2 CH(OH)CH2 OH, CF3 SO2 --, R3 R4 N--, --OCH2 CO2 R3, --NR3 COR3, --OCONH2, --OCONR3 R4, --CONH2, --CONR3 R4, --CR3 R3 R4, --SO2 NR3 R4, --SONR3 R4, CH3 OCH2 ONR3 R6, --SNR3 R4, --CO2 R3, --NR3 R4 SO2 R3, --NR3 R4 SOR, --COR3, --CONR3, --NO2, --CN, --N(R5)CONR3 R4, --CH2 N(R5)CONR3 R4, --R6 NR3 R4, --OR6 NR3 R4, --O(O)CR5, --O(O)CNR3 R4, --OR6, --SR6 NR3 R4, --S(O)R6 NR3 R4, --SO2 R6 NR3 R4, --SO2 OR6 CO;
--SR6 OH;
--S(O)R6 OH;
--SO2 R6 OH;
or --OR6 OC(O)N(CO2 R6)R6 ;
(c) a heterocycle, including but not limited to, pyrryl, furyl, pyridyl, 1,2,4-thiadiazolyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, purinyl, carbozolyl, benzamidazolyl, and isoxazolyl, optionally substituted with a group described in Y section (b);
(d) ##STR27## wherein X'"'"' is halo, --C(O)aryl, CF3, or OR3 ;
--NR3 COR3 ;
--OCONH2 ;
--CR3 R3 R4 ;
--CH2 OR3 ;
--CH2 OR3 ;
--CH2 CO2 R3 ;
--CH2 OCOR3 ;
R3 CH(R3)CH2 SO3 --;
--NHCH2 COOR3 ;
halo such as F, Cl, Br and I;
N+ R3 R3 R4 R7 ;
--NR3 SO2 R3 ;
COR3 ;
NO2 ;
or CN;
or ##STR28## wherein R13, R14 and R15 independently represents;
BO-- wherein B is --CH2 --oxacyclopropyl, --CH2 OR3, --CH2 C(O)R3, --CH2 CH(R3)R3, --CH2 Aryl, --CH2 CH(OH) --CH2 OH;
R3 C(R3) 2 CH2 SO2 ;
or R13 --R14 or R14 --R15 are joined together to form a bridge such as --OCHR2 CHR2 --S(O)n wherein n is 0 to 3;
or ##STR29## where X'"'"' is halo, --C(O)aryl, CF3, or OR3 ;
--CH2 OR3 ;
--CH2 CO2 R3 ;
--CH2 COR3 ;
--NHCH2 COOR3 ;
--N+ R3 R3 R4 R7 --,R1 and R2 are independently hydrogen, halogen, or lower alkyl, halo lower alkyl, halo, --COOH;
--CONR16 R17 wherein R16 and R17 independently represent C1-6 alkyl and hydrogen, --COOR3, alkenyl, --COR3 ;
--CH2 OR3 ;
lower alkynyl, CH2 NR4 R3 ;
--CH2 SR3 ;
═
O;
--OR3 ;
or --NR3 R3 ;
R3 and R4 are independently cyclic and acyclic alkyl, alkenyl, alkynyl, aryl, aralkyl, alkyaryl, hydrogen, C1-6 alkoxy-C1-10 alkyl, C1-6 alkylthio-C1-10 alkyl, and C1-10 substituted alkyl (wherein the substituent is independently hydroxy or carbonyl, located on any of C1-10);
R5 is cyclic and acyclic lower alkyl, lower alkenyl, lower alkynyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, aralkyl, or aryl;
R6 is cyclic and acyclic lower alkyl, lower alkenyl, lower alkynyl, aralkyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, or aryl;
R7 is an organic or inorganic anion;
R8 is halo alkyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, lower alkenyl, lower alkynyl, aralkyl, or aryl;
R9 is independently hydrogen, halogen, lower alkyl, halo lower alkyl, lower alkenyl, lower alkynyl, --CONR3 R4, --COR5, --CO2 R5, --CH2 OR5, --CH2 NR5 R5, --CH2 SR5, ═
O, ═
NR5, --NR3 R4, --NR3 R4 SR7, or --OR5 ; and
R10 is --R3, --R8, --C(O)N(OR3)R3, or --OR3,R11 is C1 to C12 alkyl;
substituted C1 to C12 alkyl wherein the substituent is selected from the group consisting of hydroxy and amino, alkenyl, lower alkoxy-alkyl;
alkylcarbonylalkyl, --alkylamino, --alkylamino(alkyl or dialkyl), lower alkyl S(O)m --lower alkyl in which m is 0, 1 or 2;
imidazolyl lower alkyl, morpholinyl lower alkyl, thiazolinyl lower alkyl, piperidinyl ower alkyl, imidazolylcarbonyl, morpholinyl carbonyl, amorpholinyl (lower alkyl) aminocarbonyl, N-pyrrylpyridinyl-lower alkyl;
pyridylthio-lower alkyl;
morpholinyl-lower alkyl;
hydroxyphenylthio-lower alkyl;
cyanophenylthio-lower alkyl;
imidazolylthio-lower alkyl;
triazolylthio-lower alkyl;
triazolylphenylthio-lower alkyl;
tetrazolylthio-lower alkyl;
tetrazolylphenylthio-lower alkyl;
aminophenylthio-lower alkyl;
N,N-di-substituted aminophenylthio-lower alkyl wherein the substituents each independently represent lower alkyl;
amidinophenylthio-lower alkyl;
phenylsulfinyl-lower alkyl;
or phenylsulfonyl lower alkyl;
R12 is selected from the group consisting of;
alkyl;
substituted alkyl wherein the substituent is selected from the group consisting of hydroxy and amino;
-lower alkyl-O-R18, wherein R18 is --PO2 (OH)-M+ or --PO3 (M+)2, wherein M+ is a pharmaceutically acceptable cation;
--C(O)(CH2)2 CO2- M+, or --SO3- M+ ;
-lower alkylcarbonyl-lower alkyl;
-carboxy lower alkyl;
-lower alkylamino-lower alkyl;
N,N-di-substituted amino lower alkyl-, wherein the substituents each independently represent lower alkyl;
pyridyl-lower alkyl;
imidazolyl-lower alkyl;
imidazolyl-Y-lower alkyl wherein Y is thio or amino;
morpholinyl-lower alkyl;
pyrrolidinyl-lower alkyl;
thiazolinyl-lower alkyl;
piperidinyl-lower alkyl;
morpholinyl-lower hydroxyalkyl;
N-pyrryl;
piperazinyl-lower alkyl;
N-substituted piperazinyl-lower alkyl, wherein the substituent is lower alkyl;
triazolyl-lower alkyl;
tetrazolyl-lower alkyl;
tetrazolylamino-lower alkyl;
or thiazolyl-lower alkyl;
R19 is H, lower alkyl, or lower alkenyl; and
R20 is H, halogen, lower alkoxy, or lower alkyl.
4 Assignments
0 Petitions
Accused Products
Abstract
2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i. e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase.
A method to treat disorders mediated by PAF or leukotrienes is also disclosed, that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.
-
Citations
18 Claims
-
1. The method for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase in an animal, comprising administering an effective amount of a compound of the formula:
- ##STR23## wherein;
X is O, S, S(O), S(O)2, CR9, or NR10 ;W is independently; (1) --AN(OM)C(O)N(R3)R4, --AN(R3)C(O)N(OM)R4, --AN(OM)C(O)R4, --AC(O)N(OM)R4, --N(OM)C(O)N(R3)R4, --N(R3) C(O)N(OM)R4, --N(OM)C(O)R4, --C(O)N(OM)R4, --OR6 N(R5)R6 --(C5 H4 N)R6 R7, --OR6 N(COR5)R6 --(C5 H4 N)R6 R7, --OR6 OC(O)N(COR5)R6 --(C5 H4 N)R6 R7, --OR6 O(CO)N(CO2 R6)R6 (C5 H4 N)R6 R7, --A(C5 H4 N)R6 R7, or --OR6 N(CO2 R5)R6 --(C5 H4 N)R6 R7; (2) an amidohydroxyurea of the formula;
--N(R19)C(O)C(R19)N(OM)C(O)NHR20, --C(O)N(R19)C(R19)N(OM)C(O)NHR20, --AN(R19)C(O)C(R19)N(OM)C(O)NHR20, --AC(O)N(R19)C(R19)N(OM)C(O)NHR20, --NHC(O)N(OM)C(R19)C(O)N(R19)2 ;
or --NHC(O)N(OM)C(R19)N(R19)C(O)R19 ;(3) an oxalkane of the structure;
##STR24## wherein n and m are independently 1-4;(4) a thioalkane of the structure;
##STR25## or (5) a quinolylmethoxy of the structure;
##STR26## n is 1 or 2;
m is 1, 2 or 3;p is 0 or 1; A is alkyl, alkenyl, alkynyl, alkyaryl, aralkyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, --C1-10 alkyl(oxy)C1-10 alkyl, --C1-10 alkyl(thio)C1-10 alkyl, --N(R3)C(O)alkyl, --N(R3)C(O)alkenyl, --N(R3)C(O)alkynyl, --N(R3)C(O)(alkyl)oxy(alkyl), --N(R3)C(O) (alkyl)thio(alkyl), --N(R3)C(O)N(alkyl), --N(R3)C(O)N(alkenyl), --N(R3)C(O)N(alkynyl), --N(R3)C(O)N(alkyl)oxy(alkyl), --N(R3)C(O)N(alkyl)thio(alkyl), --N(R3)C(O2)alkyl, --N(R3)C(O2)alkenyl, --N(R3)C(O2)alkynyl, --N(R3)C(O2)(alkyl)oxy(alkyl), --N(R3)C(O2)(alkyl)thio(alkyl) --OC(O2)alkyl, --OC(O2)alkenyl, --OC(O2)alkynyl, --OC(O2)(alkyl)oxy(alkyl), --OC(O2)(alkyl)thio(alkyl), --N(R3)C(S)alkyl, --N(R3)C(S)alkenyl, --N(R3)C(S)alkynyl, --N(R3)C(S)(alkyl)oxy(alkyl), --N(R3)C(S)(alkyl)thio(alkyl), --N(R3)C(S)N(alkyl), --N(R3)C(S)N(alkenyl), --N(R3)C(S)N(alkynyl), --N(R3)C(S)N(alkyl)oxy(alkyl), --N(R3)C(S)N(alkyl)thio(alkyl), --N(R3)C(S)S(alkyl), --N(R3)C(S)S(alkenyl), --N(R3)C(S)S(alkynyl), --N(R3)C(S)S(alkyl)oxy(alkyl), --N(R3)C(S)S(alkyl)thio(alkyl), --SC(S)S(alkyl), --SC(S)S(alkenyl), --SC(S)S(alkynyl), --SC(S)S(alkyl)oxy(alkyl), and --SC(S)S(alkyl)thio(alkyl); M is hydrogen, a pharmaceutically acceptable cation, or a metabolically cleavable leaving group; Y is independently; (a) hydrogen; (b) R1-6, R8, R10, --OR3, --OR11, --OR12, R3 S--, R5 S, R3 SO--, R5 SO--, R3 SO2 --, R5 SO2 --, CF3 O--, CF3 S--, CF3 SO--, --CF3 SO2, --OCH2 oxycyclopropyl, --OCH2 C(O)OR3, --OCH2 OR3, --OCH2 C(O)R3, --OCH2 C3-8 cycloalkyl, --OCH2 CH(R)R3, --OCH2 cyclopropyl, --OCH2 --aryl, --OCH2 CH(OH)CH2 OH, aryl--CH2 --SO2 --, (R3)2 CHCH2 SO2 --, --CH2 CH(OH)CH2 OH, CF3 SO2 --, R3 R4 N--, --OCH2 CO2 R3, --NR3 COR3, --OCONH2, --OCONR3 R4, --CONH2, --CONR3 R4, --CR3 R3 R4, --SO2 NR3 R4, --SONR3 R4, CH3 OCH2 ONR3 R6, --SNR3 R4, --CO2 R3, --NR3 R4 SO2 R3, --NR3 R4 SOR, --COR3, --CONR3, --NO2, --CN, --N(R5)CONR3 R4, --CH2 N(R5)CONR3 R4, --R6 NR3 R4, --OR6 NR3 R4, --O(O)CR5, --O(O)CNR3 R4, --OR6, --SR6 NR3 R4, --S(O)R6 NR3 R4, --SO2 R6 NR3 R4, --SO2 OR6 CO;
--SR6 OH;
--S(O)R6 OH;
--SO2 R6 OH;
or --OR6 OC(O)N(CO2 R6)R6 ;(c) a heterocycle, including but not limited to, pyrryl, furyl, pyridyl, 1,2,4-thiadiazolyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, purinyl, carbozolyl, benzamidazolyl, and isoxazolyl, optionally substituted with a group described in Y section (b); (d) ##STR27## wherein X'"'"' is halo, --C(O)aryl, CF3, or OR3 ;
--NR3 COR3 ;
--OCONH2 ;
--CR3 R3 R4 ;
--CH2 OR3 ;
--CH2 OR3 ;
--CH2 CO2 R3 ;
--CH2 OCOR3 ;
R3 CH(R3)CH2 SO3 --;
--NHCH2 COOR3 ;
halo such as F, Cl, Br and I;
N+ R3 R3 R4 R7 ;
--NR3 SO2 R3 ;
COR3 ;
NO2 ;
or CN;
or ##STR28## wherein R13, R14 and R15 independently represents;
BO-- wherein B is --CH2 --oxacyclopropyl, --CH2 OR3, --CH2 C(O)R3, --CH2 CH(R3)R3, --CH2 Aryl, --CH2 CH(OH) --CH2 OH;
R3 C(R3) 2 CH2 SO2 ;
or R13 --R14 or R14 --R15 are joined together to form a bridge such as --OCHR2 CHR2 --S(O)n wherein n is 0 to 3;
or ##STR29## where X'"'"' is halo, --C(O)aryl, CF3, or OR3 ;
--CH2 OR3 ;
--CH2 CO2 R3 ;
--CH2 COR3 ;
--NHCH2 COOR3 ;
--N+ R3 R3 R4 R7 --,R1 and R2 are independently hydrogen, halogen, or lower alkyl, halo lower alkyl, halo, --COOH;
--CONR16 R17 wherein R16 and R17 independently represent C1-6 alkyl and hydrogen, --COOR3, alkenyl, --COR3 ;
--CH2 OR3 ;
lower alkynyl, CH2 NR4 R3 ;
--CH2 SR3 ;
═
O;
--OR3 ;
or --NR3 R3 ;R3 and R4 are independently cyclic and acyclic alkyl, alkenyl, alkynyl, aryl, aralkyl, alkyaryl, hydrogen, C1-6 alkoxy-C1-10 alkyl, C1-6 alkylthio-C1-10 alkyl, and C1-10 substituted alkyl (wherein the substituent is independently hydroxy or carbonyl, located on any of C1-10); R5 is cyclic and acyclic lower alkyl, lower alkenyl, lower alkynyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, aralkyl, or aryl; R6 is cyclic and acyclic lower alkyl, lower alkenyl, lower alkynyl, aralkyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, or aryl; R7 is an organic or inorganic anion; R8 is halo alkyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, lower alkenyl, lower alkynyl, aralkyl, or aryl; R9 is independently hydrogen, halogen, lower alkyl, halo lower alkyl, lower alkenyl, lower alkynyl, --CONR3 R4, --COR5, --CO2 R5, --CH2 OR5, --CH2 NR5 R5, --CH2 SR5, ═
O, ═
NR5, --NR3 R4, --NR3 R4 SR7, or --OR5 ; andR10 is --R3, --R8, --C(O)N(OR3)R3, or --OR3, R11 is C1 to C12 alkyl;
substituted C1 to C12 alkyl wherein the substituent is selected from the group consisting of hydroxy and amino, alkenyl, lower alkoxy-alkyl;
alkylcarbonylalkyl, --alkylamino, --alkylamino(alkyl or dialkyl), lower alkyl S(O)m --lower alkyl in which m is 0, 1 or 2;
imidazolyl lower alkyl, morpholinyl lower alkyl, thiazolinyl lower alkyl, piperidinyl ower alkyl, imidazolylcarbonyl, morpholinyl carbonyl, amorpholinyl (lower alkyl) aminocarbonyl, N-pyrrylpyridinyl-lower alkyl;
pyridylthio-lower alkyl;
morpholinyl-lower alkyl;
hydroxyphenylthio-lower alkyl;
cyanophenylthio-lower alkyl;
imidazolylthio-lower alkyl;
triazolylthio-lower alkyl;
triazolylphenylthio-lower alkyl;
tetrazolylthio-lower alkyl;
tetrazolylphenylthio-lower alkyl;
aminophenylthio-lower alkyl;
N,N-di-substituted aminophenylthio-lower alkyl wherein the substituents each independently represent lower alkyl;
amidinophenylthio-lower alkyl;
phenylsulfinyl-lower alkyl;
or phenylsulfonyl lower alkyl;R12 is selected from the group consisting of;
alkyl;
substituted alkyl wherein the substituent is selected from the group consisting of hydroxy and amino;
-lower alkyl-O-R18, wherein R18 is --PO2 (OH)-M+ or --PO3 (M+)2, wherein M+ is a pharmaceutically acceptable cation;
--C(O)(CH2)2 CO2- M+, or --SO3- M+ ;
-lower alkylcarbonyl-lower alkyl;
-carboxy lower alkyl;
-lower alkylamino-lower alkyl;
N,N-di-substituted amino lower alkyl-, wherein the substituents each independently represent lower alkyl;
pyridyl-lower alkyl;
imidazolyl-lower alkyl;
imidazolyl-Y-lower alkyl wherein Y is thio or amino;
morpholinyl-lower alkyl;
pyrrolidinyl-lower alkyl;
thiazolinyl-lower alkyl;
piperidinyl-lower alkyl;
morpholinyl-lower hydroxyalkyl;
N-pyrryl;
piperazinyl-lower alkyl;
N-substituted piperazinyl-lower alkyl, wherein the substituent is lower alkyl;
triazolyl-lower alkyl;
tetrazolyl-lower alkyl;
tetrazolylamino-lower alkyl;
or thiazolyl-lower alkyl;R19 is H, lower alkyl, or lower alkenyl; and R20 is H, halogen, lower alkoxy, or lower alkyl. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
- ##STR23## wherein;
Specification